Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price14.53 USD
Fair value14.64
Ethical score70.0/100
Our investment reviews on this name
2026-07-02Read Distribution22.00-34.0% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The Chemours Company holds its Markdown at $14.53. Consolidating, no directional conviction, held for 10 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 10 days
Price at the screen
$14.53
Valuation
N/A trailing · 7.54 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.42
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
59.52%
Below 33%
Interest-bearing debt is 59.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
16.69%
Below 49%
Money owed to the company is 16.7% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 0.8% margin of safety to the base estimate.
Third-party analyst targets: 9 covering, consensus Buy. The average target sits +24% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chemicals giant's low multiple hides a classic cycle trap
Picture a factory running flat out one year and idling the next as construction and car makers turn the tap on and off. Chemours sits in exactly that spot, with revenue barely rising one percent and margins already deep in the red. The forward multiple looks tempting at seven point eight times, yet history shows these peaks rarely last and the current numbers offer no margin of safety.
We therefore pass. Our own fair value sits only nine percent above the price, producing an opportunity rating of none, and the negative return on equity of one hundred three percent signals real pressure on the balance sheet. Analyst targets may sit higher, but they ignore how quickly earnings can collapse once demand fades in this sector.
Ethical screens clear the company, yet the combination of wafer thin growth and deeply negative profitability outweighs any headline cheapness. Cyclical businesses at low multiples have a habit of staying cheap for good reason once the cycle turns. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CC trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-24Distribution$15.75-10.1%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $26.
2026-07-24Distribution$17.52-20.4%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 20.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $26.
2026-07-18Distribution$22.00+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 36% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 76%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (9 analysts) rates it buy, with a mean price target of $26.
2026-07-03Distribution$22.00+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Distribution$22.00Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
